Research and development of new drugs for nonalcoholic steatohepatitis: An unmet need in clinical practice
DOI:10.3969/j.issn.1001-5256.2021.06.001
- VernacularTitle:非酒精性脂肪性肝炎新药研发： 一个未被满足的临床需求
- Author:
Yining HE
1
;
Junping SHI
Author Information
1. School of Clinical Medicine, Hangzhou Normal University Medical College, Hangzhou 310018, China
- Publication Type:Research Article
- Keywords:
Non-alcoholic Fatty Liver Disease;
Drug Discovery;
Clinical Trial
- From:
Journal of Clinical Hepatology
2021;37(6):1241-1244
- CountryChina
- Language:Chinese
-
Abstract:
With the effective control of viral hepatitis around the world, nonalcoholic steatohepatitis (NASH) will become the main cause of liver transplantation in the next ten years. There is a huge number of NASH patients, but currently no drug has been approved by authorities, which represents a large unmet need in clinical practice. The complex pathogenesis of NASH, heterogeneity of this disease, difficulties in diagnosis, and selection of treatment endpoints have brought great challenges to the research and development of new drugs.
